BAGSVAERD, DENMARK--(Marketwired - May 01, 2013) - Financial report for the period 1
January 2013 to 31 March 2013.
Sales growth of 13% driven by Victoza®, NovoRapid® and Levemir
Company announcement No 32 / 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE